none
Conditions
Sponsors
UZLeuven
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy volunteers (18-45 years) who have no bowel symptoms and who are in good general health are eligible for the study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • They have relevant underlying disease (cardia, pulmonary, metabolic, kidney or liver disease, … ) • They have a history of esophageal or gastric surgery, or recurrent or intermittent upper gastrointestinal symptoms (upper abdominal pain, nausea, vomiting, bothersome fullness or early satiation, heartburn, regurgitation,…) • They have a history of allergy to several types of drugs or food. • They have ever been treated for depression • They use cannabinoids. • There is a possibility of becoming pregnant during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate a potential contribution of CB1 pathways in the control of esophageal function, we want to study esophageal contractility and LES tone after pretreatment with rimonabant, a blocker of the CB1 receptor used clinically in the treatment of obesity. ;Secondary Objective: /;Primary end point(s): The trial will evaluate a dual primary endpoint: 1) Postprandial pressure in the lower esophageal sphincter 2) The number of transiënt lower esophageal sphincter relaxations after a meal | — |
Countries
Belgium
Outcome results
None listed